Genetic mutations linked to poor outcomes in Pluvicto patients TP53, PTEN, and RB1 mutations may serve as prognostic biomarkers.

Patients with certain genetic mutations have inferior overall survival after treatment with lutetium-177 (Lu-177) prostate-specific membrane antigen 617 (PSMA-617) #radiology #prostatecancer #Pluvicto

Novartis CEO projects 2026 growth despite ‘largest patent expiry’ in company history Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter

#Novartis #VasNarasimhan #patentexpirations #patentcliff #Entresto #Pluvicto #Kisqali #BTKinhibitors #PSMAtargetedradioligandtherapy #prostatecancer #BTKinhibitor #chronicspontaneousurticaria #multiplesclerosis #Rhapsido #relapsingMS #MS #antibodies #Bcellpathways #Kesimpta
zurl.co/n0N8z

The World Series has some really wild pharma commercials!
#pluvicto #frightnight

THERANOSTICS

WHAT IS IT? Answer below..
Why should you care?? It is improving outcomes for men with #prostate #cancer - #Pluvicto
#Bayer #Novartis #FinishCancer #ASTRO2025 #PCF @prostatecanceruk.bsky.social @ipcr.bsky.social @ip-london.bsky.social #CRUK @cruk-mi.bsky.social @prostates.bsky.social

🧐???? #THERANOSTICS ????

Looking forward to hearing the first two keynotes at THERANOSTICS conference being held at the new #Discovery building at @uwiscradiology.bsky.social @uwiscpress.bsky.social
#cancer #radiation #Therapy #ASTRO #FinishCancer #Pluvicto #Novartis #PCF #ProstateCancer

Novartis’ Pluvicto shown to slow prostate cancer in earlier setting 0 NOVN 1.36% NVSEF -1.82% NOVN hereremove ads 0 Latest comments Install Our AppScan QR code to install app Google Play App Store Blog Mobile Portfolio Widgets About Us Advertise Help & Support Authors Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #ProstateCancer #Pluvicto #Novartis #CancerResearch #HealthInnovation

Pluvicto (177Lu-PSMA-617): Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily Pluvicto (177Lu-PSMA-617): Uses in Cancer, Side Effects, Dosage, Expectations, and More / 177Lu-PSMA-617, Cancer research, cancer treatment, Drugs, FDA, FDA

Pluvicto (177Lu-PSMA-617): Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/pluvic...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Pluvicto #ProstateCancer #mCRPC

SPECT/CT predicts overall survival in Pluvicto patients New evidence supports using SPECT/CT scans along with serum PSA levels to evaluate early patient responses to Pluvicto treatment.

Novel data from LMU in Munich supports using #SPECTCT scans along with serum PSA levels to evaluate early patient responses to #Pluvicto treatment. buff.ly/7DSDgl7 #radiology #nuclearmedicine

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Pluvicto #ProstateCancer #mCRPC

FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer.

Big news in prostate cancer treatment! The #FDA has expanded the label for Novartis #Pluvicto, now approved before chemotherapy for PSMA-positive metastatic castration-resistant prostate cancer. #TCSC #cancerresearch #prostatecancer #psmafore

www.appliedclinicaltrialsonline.com/view/fda-app...

#Pluvicto is the perfect brand name for a drug because it means Victorious Pluto, God of Death and those side effects will kill you.

1/2 #Pluvicto therapy for advanced #prostatecancer. [Excerpt] Blue Cure Men's Health Podcast with guest, Dr. Umber Salman, UT Health San Antonio.

[Learn more] Game-changing prostate cancer treatment available at UT Health San Antonio: news.uthscsa.edu/game-changin...

ノバルティス、第3四半期売上高10％増、堅調な業績を継続し通期予想上方修正 製薬大手ノバルティスが2024年第3四半期の決算を発表。売上高は10％増、コア営業利益は20％増と大幅増益。主力製品の好調に加え、米国での承認取得も業績を押し上げた。通期業績予想も上方修正され、今後の成長に期待が高まる。

ノバルティス、第3四半期売上高10％増、堅調な業績を継続し通期予想上方修正 #ノバルティス #Kisqali #Pluvicto

製薬大手ノバルティスが2024年第3四半期の決算を発表。売上高は10％増、コア営業利益は20％増と大幅増益。主力製品の好調に加え、米国での承認取得も業績を押し上げた。通期業績予想も上方修正され、今後の成長に期待が高まる。